For most early-stage BC patients, the standard treatment strategy is the performance of breast-conserving surgery (BCS) followed by adjuvant whole breast radiotherapy (RT) and adjuvant endocrine therapy (ET) based on hormone receptor status (2). This evidence concerns the gene NR4A1 and breast cancer.